Robert Thomas Booth, MD - Medicare Anesthesiology in Temple, TX

Robert Thomas Booth, MD is a medicare enrolled "Anesthesiology" physician in Temple, Texas. His current practice location is 2401 S 31st St, Temple, Texas. You can reach out to his office (for appointments etc.) via phone at (254) 724-5306.

Robert Thomas Booth is licensed to practice in Texas (license number BP10040117) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1205129301.

Contact Information

Robert Thomas Booth, MD
2401 S 31st St,
Temple, TX 76508-0001
(254) 724-5306
Not Available



Physician's Profile

Full NameRobert Thomas Booth
GenderMale
SpecialityAnesthesiology
Location2401 S 31st St, Temple, Texas
Accepts Medicare AssignmentsMedicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.
  NPI Data:
  • NPI Number: 1205129301
  • Provider Enumeration Date: 05/23/2011
  • Last Update Date: 05/23/2011
  Medicare PECOS Information:
  • PECOS PAC ID: 0042529844
  • Enrollment ID: I20151019000511

Medical Identifiers

Medical identifiers for Robert Thomas Booth such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1205129301NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207L00000XAnesthesiology BP10040117 (Texas)Primary

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Robert Thomas Booth allows following entities to bill medicare on his behalf.
Entity NameNorthstar Anesthesia Pa
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1912978610
PECOS PAC ID: 7315907128
Enrollment ID: O20041015000685

News Archive

Screening for cardiovascular risk by measuring blood levels of C-reactive protein should not be advocated

C-reactive protein (CRP) is released by the liver in response to inflammation related to an infection, injury, or conditions such as arthritis. Inflammation also has been associated with the cause and progression of cardiovascular disease, particularly in the build up of fatty deposits in the lining of arteries.

Important differences found in characteristics, progression of lupus among racial/ethnic groups

In the first epidemiologic study comparing lupus among four major racial/ethnic groups, researchers found that, following a lupus diagnosis, Blacks, Asians/Pacific Islanders, and Hispanics are at increased risk of developing problems related to the kidneys, the neurological system, and the blood.

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

Read more Medical News

› Verified 1 days ago

Entity NameAnesthesia Company Of Houston, Pllc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1598038770
PECOS PAC ID: 4284897299
Enrollment ID: O20120531000130

News Archive

Screening for cardiovascular risk by measuring blood levels of C-reactive protein should not be advocated

C-reactive protein (CRP) is released by the liver in response to inflammation related to an infection, injury, or conditions such as arthritis. Inflammation also has been associated with the cause and progression of cardiovascular disease, particularly in the build up of fatty deposits in the lining of arteries.

Important differences found in characteristics, progression of lupus among racial/ethnic groups

In the first epidemiologic study comparing lupus among four major racial/ethnic groups, researchers found that, following a lupus diagnosis, Blacks, Asians/Pacific Islanders, and Hispanics are at increased risk of developing problems related to the kidneys, the neurological system, and the blood.

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

Read more Medical News

› Verified 1 days ago

Entity NameNorthstar Anesthesia Ii Pa
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1477066405
PECOS PAC ID: 2365701737
Enrollment ID: O20180110000102

News Archive

Screening for cardiovascular risk by measuring blood levels of C-reactive protein should not be advocated

C-reactive protein (CRP) is released by the liver in response to inflammation related to an infection, injury, or conditions such as arthritis. Inflammation also has been associated with the cause and progression of cardiovascular disease, particularly in the build up of fatty deposits in the lining of arteries.

Important differences found in characteristics, progression of lupus among racial/ethnic groups

In the first epidemiologic study comparing lupus among four major racial/ethnic groups, researchers found that, following a lupus diagnosis, Blacks, Asians/Pacific Islanders, and Hispanics are at increased risk of developing problems related to the kidneys, the neurological system, and the blood.

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

Read more Medical News

› Verified 1 days ago

Entity NameNorthstar Anesthesia Iii Pa
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1356968952
PECOS PAC ID: 0042630501
Enrollment ID: O20201022000080

News Archive

Screening for cardiovascular risk by measuring blood levels of C-reactive protein should not be advocated

C-reactive protein (CRP) is released by the liver in response to inflammation related to an infection, injury, or conditions such as arthritis. Inflammation also has been associated with the cause and progression of cardiovascular disease, particularly in the build up of fatty deposits in the lining of arteries.

Important differences found in characteristics, progression of lupus among racial/ethnic groups

In the first epidemiologic study comparing lupus among four major racial/ethnic groups, researchers found that, following a lupus diagnosis, Blacks, Asians/Pacific Islanders, and Hispanics are at increased risk of developing problems related to the kidneys, the neurological system, and the blood.

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

Read more Medical News

› Verified 1 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Robert Thomas Booth is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Robert Thomas Booth, MD
4513 Stagecoach Trl,
Temple, TX 76502-3869

Ph: (806) 317-2017
Robert Thomas Booth, MD
2401 S 31st St,
Temple, TX 76508-0001

Ph: (254) 724-5306

News Archive

Screening for cardiovascular risk by measuring blood levels of C-reactive protein should not be advocated

C-reactive protein (CRP) is released by the liver in response to inflammation related to an infection, injury, or conditions such as arthritis. Inflammation also has been associated with the cause and progression of cardiovascular disease, particularly in the build up of fatty deposits in the lining of arteries.

Important differences found in characteristics, progression of lupus among racial/ethnic groups

In the first epidemiologic study comparing lupus among four major racial/ethnic groups, researchers found that, following a lupus diagnosis, Blacks, Asians/Pacific Islanders, and Hispanics are at increased risk of developing problems related to the kidneys, the neurological system, and the blood.

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

Read more News

› Verified 1 days ago


Anesthesiology Doctors in Temple, TX

Taylor Pohler, M.D.
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 832-928-0760    
Dr. Justin Michael Koenemann, DO
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 2401 S 31st., Temple, TX 76508
Phone: 254-724-2111    
David Michel Cousineau,
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 254-724-2111    
Dair Chevalier, M.D.
Anesthesiology
Medicare: Medicare Enrolled
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 254-724-2111    
Dr. Olen E. Kitchings Iii, M.D.
Anesthesiology
Medicare: Not Enrolled in Medicare
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 254-724-2111    
Bryan Rondeau, M.D.
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 254-724-2111    
Dr. David P. Ciceri, M.D.
Anesthesiology
Medicare: Accepting Medicare Assignments
Practice Location: 2401 S 31st St, Temple, TX 76508
Phone: 254-724-2111    

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.